Skip to main content
Vaishalee Kenkre, MD, Oncology, Madison, WI

VaishaleePadgaonkarKenkreMD

Oncology Madison, WI

Hematologic Oncology

Associate Professor, Medicine, University of Wisconsin Medical School

Dr. Kenkre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kenkre's full profile

Already have an account?

  • Office

    600 Highland Ave
    Madison, WI 53792
    Phone+1 608-265-1700

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 2004 - 2007
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 2004

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2010 - 2025
  • IL State Medical License
    IL State Medical License 2007 - 2014
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • UW Study Provides Potential Treatment Strategy for Aggressive Lymphoma
    UW Study Provides Potential Treatment Strategy for Aggressive LymphomaJune 12th, 2019